A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
University of Nebraska
SecuraBio
SecuraBio
University of California, San Francisco
Fondazione Italiana Linfomi - ETS
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Polish Lymphoma Research Group
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
University of California, Davis
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Gilead Sciences
M.D. Anderson Cancer Center
German CLL Study Group
Pharmacyclics LLC.
University Health Network, Toronto
M.D. Anderson Cancer Center
Novartis
Mayo Clinic
Novartis
University of California, San Diego
University of Oxford
National Cancer Institute (NCI)
Novartis
SCRI Development Innovations, LLC
GlaxoSmithKline
GlaxoSmithKline
Massachusetts General Hospital
SCRI Development Innovations, LLC
GlaxoSmithKline
GlaxoSmithKline
Merck Sharp & Dohme LLC
Novartis
Niguarda Hospital
SCRI Development Innovations, LLC
Technische Universität Dresden
National Cancer Centre, Singapore
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Medical University of South Carolina